Intraductal papillary mucinous neoplasias (IPMNs) are precancerous cystic lesions that can develop into pancreatic ductal adenocarcinomas (PDACs). These large macroscopic lesions are frequently detected during medical imaging, but it is unclear how they form or progress to PDAC. We aimed to identify cells that form IPMNs and mutations that promote IPMN development and progression. METHODS: We generated mice with disruption of Pten specifically in ductal cells (Sox9CreER T2 P ancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with a 5-year survival rate of approximately 9%. PDAC is preceded by the formation of noninvasive premalignant lesions. Based on histological appearance and size, premalignant lesions have been classified into 3 major subtypes, namely microscopic pancreatic intraepithelial neoplasias (PanINs), macroscopic intraductal papillary mucinous neoplasias (IPMNs), and mucinous cystic neoplasias (MCNs). In recent years, the cystic neoplasias (IPMNs and MCNs) have gained attention because improvements in medical imaging have led to higher rates of incidental identification of these lesions.
BACKGROUND & AIMS:
Intraductal papillary mucinous neoplasias (IPMNs) are precancerous cystic lesions that can develop into pancreatic ductal adenocarcinomas (PDACs). These large macroscopic lesions are frequently detected during medical imaging, but it is unclear how they form or progress to PDAC. We aimed to identify cells that form IPMNs and mutations that promote IPMN development and progression. METHODS: We generated mice with disruption of Pten specifically in ductal cells (Sox9CreER T2 ;Pten flox/flox ; R26R YFP or Pten DDuct/DDuct mice) and used Pten DDuct/þ and Pten þ/þ mice as controls. We also generated Kras G12D ; Pten DDuct/DDuct and Kras G12D ;Pten DDuct/þ mice. Pancreata were collected when mice were 28 weeks to 14.5 months old and analyzed by histology, immunohistochemistry, and electron microscopy. We performed multiplexed droplet digital polymerase chain reaction to detect spontaneous Kras mutations in Pten DDuct/DDuct mice and study the effects of Ras pathway activation on initiation and progression of IPMNs. We obtained 2 pancreatic sections from a patient with an invasive pancreatobiliary IPMN and analyzed the regions with and without the invasive IPMN (control tissue) by immunohistochemistry. RESULTS: Mice with ductal cellspecific disruption of Pten but not control mice developed sporadic, macroscopic, intraductal papillary lesions with histologic and molecular features of human IPMNs. Pten In analyses of mice with ductal cell-specific disruption of Pten, with or without activated Kras, we found evidence for a ductal cell origin of IPMNs. We also showed that PTEN loss and activated Kras have synergistic effects in promoting development of IPMN and progression to PDAC. P ancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with a 5-year survival rate of approximately 9%. PDAC is preceded by the formation of noninvasive premalignant lesions. Based on histological appearance and size, premalignant lesions have been classified into 3 major subtypes, namely microscopic pancreatic intraepithelial neoplasias (PanINs), macroscopic intraductal papillary mucinous neoplasias (IPMNs), and mucinous cystic neoplasias (MCNs). In recent years, the cystic neoplasias (IPMNs and MCNs) have gained attention because improvements in medical imaging have led to higher rates of incidental identification of these lesions. 1 IPMNs comprise 20% to 50% of all pancreatic cystic neoplasms. 1 Although the 5-year survival rate of individuals with noninvasive IPMN is excellent (>77%), the presence of an invasive component drops the 5-year survival rate to 34% to 62%. 1 Currently, the malignant potential of pancreatic cysts is difficult to predict. To enable effective selection for curative surgical intervention, strategies that distinguish benign cysts from lesions with high malignant potential are needed.
An important criterion influencing IPMN prognosis is the location within the pancreatic ductal system. Although branch-duct IPMN has a low risk for malignant progression, individuals with main-duct IPMN are at high risk. 1 The histological IPMN subtype is another prognostic criterion, with intestinal, oncocytic, and gastric IPMN having a more favorable prognosis than pancreatobiliary IPMN. 2, 3 However, highconfidence biomarkers to distinguish IPMN with low and high malignant potential or IPMN subtypes are lacking because very little is known about IPMN development.
Several reports have shown that dysregulation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is associated with IPMN-PDAC compared with conventional PDAC. [4] [5] [6] [7] [8] In addition, genetic studies suggest that gastric and pancreatobiliary IPMNs have a higher frequency of KRAS mutations than intestinal and oncocytic IPMNs. 9, 10 However, the lack of a genetically tractable animal model for IPMNs has hampered studies of how these mutations affect the initiation, progression, or subtype identity of IPMN.
IPMN-like cystic lesions have been observed in several mouse models. For example, Kras G12D (LSL-Kirsten Rat Sarcoma Viral Oncogene Homolog G12D allele) expression in combination with Elastase promoter-driven transforming growth factor-alpha expression, or loss of Brahma ProteinLike 1 (Brg1), Activin receptor type 1b, TIFg (Transcriptional Intermediary Factor 1 gamma), or Smad4 (Mothers Against Decapentaplegic Homolog 4) causes cystic, IPMNlike lesions. [11] [12] [13] [14] [15] However, the genetic events in these studies were induced widely in embryonic pancreatic precursors, leading to genetic changes in all pancreatic cells and consequently displacement of most normal pancreatic tissue by cystic and PanIN lesions. The similarity of these mouse models to human IPMNs, where lesions are usually solitary, is limited. Moreover, the pancreas-wide induction of the genetic events precluded studies addressing the cellular origin of the cystic lesions and associated PDAC. von Figura and colleagues 14 recently proposed a ductal origin for IPMN based on their observation that ductal-cell-specific manipulation of Kras and Brg1 induced structures resembling precancerous lesions. However, because these animals could be followed for only 6 weeks, it remained unclear whether these lesions develop into macroscopic IPMN that progress to PDAC. Thus, mouse models fully recapitulating the features of human IPMN and associated PDAC are still missing.
Here, we use ductal-cell-specific manipulation of the PI3K pathway to create a new mouse model that forms macroscopic IPMN lesions of multiple histological subtypes, recapitulating the clinicopathological features of human IPMN. Our analysis of this model provides insight into the cellular origin of IPMN and the subtype-specific genetic mutations that underlie IPMN formation and progression.
EDITOR'S NOTES

BACKGROUND AND CONTEXT
Intraductal papillary mucinous neoplasia (IPMN) is suggested to arise from the pancreatic ducts, but evidence to directly support this conclusion is lacking.
NEW FINDINGS
Deletion of Pten specifically in mouse ductal cells results in IPMN lesions with the potential to progress to pancreatic ductal adenocarcinoma. Additionally, oncogenic Kras combined with PTEN loss is associated with the progression of IPMN to invasive disease.
LIMITATIONS
A larger study is needed to determine how often these events occur in human disease.
IMPACT
The authors generated a mouse model ideal for studying the relevance of IPMN-related allelic variants and demonstrated that Kras and PTEN loss may be indicative of malignant IPMN. 
Histology and Immunohistochemical Analysis
Paraffin-embedded sections were subjected to hematoxylin (Mayer's or Harris formulations), eosin, or immunohistochemical staining as described. 21, 22 High-or low-resolution scans of entire slides were generated using a Zeiss (Oberkochen, Germany) AxioScan.Z1 or a Zeiss Apoptome microscope, respectively. In combination with necropsy images, whole slide images were used to identify pancreatic duct dilation and presence of papillary nodules/ lesions. These images were also used to determine the IPMN subtype, IPMN location, and pre-IPMN and PanIN numbers. Papillary lesions resembling larger IPMN and associated with microscopic, but not macroscopic, duct dilation were classified as a pre-IPMN. Macroscopic tumors associated with lesions in microscopically, but not macroscopically, dilated ducts were classified as pre-IPMN-or PanINassociated PDAC depending on the presence of papillae. All other microscopic preneoplastic changes in the duct were classified as PanIN.
A list of primary and secondary antibodies used for immunohistochemistry can be found in Supplementary  Table 1 . The percentage of Ki67-positive cells in large (main and interlobular ducts) and small ducts (intercalated and terminal ducts and centroacinar cells) was quantified from Ki67-stained slides counterstained with hematoxylin. At least 10 Â20 images from each animal were analyzed. Electron microscopy was performed as described. 21 Immunohistochemical staining for phosphorylated Erk was evaluated by estimating the percentage of phosphorylated Erk-positive cells with signal intensity equivalent to a positive control. Strongly positive (þþþ) lesions had signal in more than 50% of cells, whereas weakly positive samples (þ) had signal in fewer than 10% of cells. Moderately positive (þþ) lesions fell between these criteria. No observed staining was scored as "not detected." All IPMN and pre-IPMN/PanIN lesions in Pten DDuct/DDuct mice were analyzed. For Mucin 1 (Muc1), Mucin 2 (Muc2), and Claudin 18 immunohistochemistry, 3 to 15 mice with lesions representing those in the common and main duct were evaluated. Pictures show representative images. PTEN immunohistochemistry signal was scored as "lost" if more than 80% of the cells in the invasive epithelium with atypical nuclear changes did not have signal. This latter distinction was made because PTEN signal was detected in stromal cells and sometimes in the epithelial wall of the cyst.
Allele-Specific Polymerase Chain Reaction (PCR), Droplet Digital PCR, and Tumor Genotyping
Areas of interest were isolated from paraffin-embedded sections using a sterilized razor blade. Nontumor areas and IPMN/PDAC areas were obtained from the same section where possible. Paraffin was removed using xylene, samples were rehydrated, and genomic DNA extracted by heating samples at 55 C overnight in 50-mM Tris-HCl pH 8.0, 20 mM NaCl, 1 mM EDTA pH 8.0, and 1% sodium dodecyl sulfate. DNA was isolated by phenol chloroform extraction using 5-PRIME Phase Lock Gel (FP2302820; Fisher Scientific, Hampton, NH) and DNA concentration determined using NanoDrop (Thermo Scientific, Waltham, MA) or Qubit. The following primers were used to detect the murine Kras G12D mutation using allele-specific PCR: wild-type forward primer 5ʹ-ATAAACTTGTGGTGGTTGGAGCTTG-3ʹ; G12D forward primer 5ʹ-ATAAACTTGTGGTGGTTGGAGCTTA-3ʹ; and a common reverse primer 5ʹ-GACTGTAGAGCAGCGTTACC-3ʹ. Primers for the Pten allele were used as described. 23 Mutant Kras was quantified using a RainDrop Plus Digital PCR System (RainDance Technologies, Lexington, MA), using a modified version of a described protocol (Pratt et al, unpublished data and Jackson et al 24 ) . Briefly, DNA (0.88 to 15.9 ng; mean: 5.0 ng) was partitioned into picoliter-sized droplets before a short PCR (98 C for 3 minutes; 9 cycles of 98 C for 10 seconds, 66.5 C for 3 minutes, 72 C for 30 seconds; 72 C for 5 minutes) using Q5 High Fidelity 2x Master Mix (New England Biolabs, Ipswich, MA), 0.5Â droplet stabilizer, and 500 nM Kras-specific primers (F: AGGCCTGCTGAAAATGACTGAG; R: TGAATTAGCTGTATCGTCAAGGCG) to amplify the input DNA. Amplification was performed within each individual droplet, thereby preserving Kras allele frequencies. Droplets were de-emulsified and amplified DNA was isolated using a MiniElute PCR Purification kit (Qiagen, Hilden, Germany) and again partitioned into droplets for PCR (95 C for 10 minutes; 45 cycles of 95 C for 15 seconds, 60 C for 1 minute; 98 C for 10 minutes) using TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA), 1Â droplet stabilizer, 900 nM of the aforementioned primers, and 100 nM each of Kras allelespecific TaqMan probes (wild-type: VIC-TTGGAGCTGGTGGCGT-MGBNFQ; G12C: 6FAM-TGGAGCTTGTGGCGT-MGBNFQ; G12D: 6FAM-TGGAGCTGATGGCGT-MGBNFQ; G12R: 6FAM-TGG AGCTCGTGGCGT-MGBNFQ; G12V: 6FAM-TGGAGCTGTTGGCGT-MGBNFQ). Absolute quantification of wild-type or mutant Kraspositive droplets was performed by detecting fluorescence within individual droplets using RainDrop Analyst II software. Baseline was the mean number of mutant droplets in controls and positive mutant populations were defined as those exceeding that mean plus 2 standard deviations.
Statistical Analysis
P values were calculated using the 2-tailed Student t test with Excel software (Microsoft Corporation, Redmond, WA).
Results
Loss of Pten in Pancreatic Ductal Cells Leads to Macroscopic Cystic IPMN Lesions
To test whether PTEN plays a role in IPMN formation, we used a genetic strategy to inducibly ablate Pten specifically in pancreatic ductal cells of mice. To simultaneously follow the fate of recombined cells that lost PTEN, tamoxifen-inducible Sox9CreER T2 mice 16 were crossed with mice harboring a Cre-recombinase-dependent yellow fluorescence protein (YFP) reporter allele (R26R YFP ) 20 and a "floxed" allele of the Pten gene 18 to generate
), and Figure 1A ). At 4 weeks of age, mice were injected 3 times with tamoxifen to induce recombination of the Pten floxed allele and expression of YFP ( Figure 1B ). At 1 month after tamoxifen injection, we observed widespread expression of YFP in large ducts, small ducts, and centroacinar cells ( Figure 1C and D, centroacinar cells, insets). As expected, PTEN expression was lost throughout the ductal tree of Pten DDuct/DDuct mice, including centroacinar cells ( Figure 1E and F, centroacinar cells, arrows in insets). These results show that we can efficiently ablate Pten in ductal cells.
To determine the effect of ductal Pten loss, we examined pancreata of 2.0-to 14.5-month-old Pten DDuct/DDuct mice. The first noticeable histological change was detected at 6.0 to 7.5 months of age, when we observed hyperplasia in large sections of the main and large ducts in Pten Figure 1A and B). To examine whether increased ductal cell proliferation caused large duct hyperplasia in the absence of Pten, we quantified the percentage of proliferating cells located in large and small ducts at 2.0, 7.5, and 12.0 months of age in Pten DDuct/DDuct and control mice using immunohistochemistry against Ki67 ( Figure 1G -L). At 7.5 months of age, the proliferation index of large ducts was 18-fold higher in Pten DDuct/DDuct than control mice and remained 10-fold higher at 12 months of age ( Figure 1M ). Pten loss had less of an effect on small duct cell proliferation ( Figure 1M ). Consistent with this observation, electron microscopy of pancreata at 7.5 months revealed no expansion of the centroacinar/terminal ductal cell compartment in Pten DDuct/DDuct mice (Supplementary Figure 1C and D, arrows). Thus, loss of Pten in ductal cells leads to proliferation and hyperplasia predominantly of large ducts.
To examine whether the observed ductal hyperplasia in 6-to 7-month-old Pten DDuct/DDuct mice was associated with neoplasia, we examined a large cohort of Pten
, and Pten þ/þ (n ¼ 34) mice at 6.0 to 14.5 months. At necropsy, we observed that the main pancreatic duct and/or common duct was visibly enlarged and dilated in 15 of 43 Pten Table 1 ). These papillae and nodules were macroscopically visible, were continuous with the ductal epithelium (Figure 2Dii , insets; Figure 2F , arrow), lacked the characteristic estrogen-receptor-positive ovariantype stroma associated with MCN ( Supplementary  Figure 2A and B), and had mucinous secretions (Supplementary Figure 2C) . The focal nature of these macroscopic lesions and their sporadic occurrence in only 34% of Pten DDuct/DDuct mice suggests a secondary clonal event leading to expansion of cells within the Ptennegative ductal epithelium. Collectively, the features observed in pancreata from Pten DDuct/DDuct mice recapitulated hallmarks of human main duct IPMN, namely dilation of the main duct and grossly visible, focal papillary lesions contiguous with the main duct. 1 Based on these similarities, we classified the lesions in Pten DDuct/ DDuct mice as main duct or common duct IPMN (Table 1) .
IPMN Lesions in Pten
DDuct/DDuct Mice Represent 2 IPMN Subtypes Morphological differences have led to the classification of human IPMNs into different subtypes. 1 The papillae in Pten DDuct/DDuct mice had 2 morphologically different appearances, suggesting different subtype identity. One type of papillae exhibited a complex arborizing morphology with predominantly single-cell-layered epithelium reminiscent of human pancreatobiliary IPMN ( however, in 1 mouse both subtypes were observed, albeit in distinct foci (Figure 2Di ; Table 1 ). Overall, pancreatobiliary IPMN was more common than oncocytic IPMN (15 vs 4 lesions).
To further investigate the similarity of IPMN-like lesions in Pten DDuct/DDuct mice with human oncocytic and pancreatobiliary IPMN, we analyzed Muc1 and Muc2 expression. Similar to human pancreatobiliary and oncocytic subtypes, which express Muc1, but not Muc2, 2 
both types of papillary lesions in Pten
DDuct/DDuct mice were Muc1-positive and Muc2-negative (Supplementary Figure 2D-G) . We further confirmed the preneoplastic nature of these lesions by showing that lesions of both subtypes express Claudin 18 (Cldn18) (Supplementary Figure 2H and I) , which is expressed in neoplastic lesions but not in normal mouse ductal cells. 25 Together, these data suggest that the PTEN-negative ductal epithelium gives rise to papillae representing the murine counterparts of pancreatobiliary or oncocytic subtypes of human IPMN.
Invasive PDAC Predominantly Associates With Pancreatobiliary IPMN in Pten
DDuct/DDuct Mice
As IPMN is a precursor lesion for invasive carcinoma, 1 we next examined whether IPMNs in Pten DDuct/DDuct mice were PanIN3 and associated PDAC observed. c Denotes lesions where pErk signal was present in the epithelial wall of the lesion, but not the papilla. When more than one mass or lesion was present and these lesions were in distinct locations within the pancreas, they were recorded as separate lesions rather than as a lesion with a mixed phenotype. In 2 mice with IPMN, microscopic tumors distant from the IPMN were also observed (Figure 2Hi,Hii) . These small well-differentiated tumors were directly adjacent to large ducts with an inflammatory reactive atypia that transitioned into epithelium with PanIN features (Figure 2Hi , inset; Table 1 , mice #63 and #168). This resembles human IPMN-PDAC, where PDAC can be found in regions distinct from the IPMN. 3 Because we observed PanIN-associated PDAC only in mice with IPMN (Table 1) and significant main-duct distention and metaplasia, PanIN-associated tumors are likely secondary to mainduct obstruction and the resulting inflammatory response. Together, these data suggest that Pten deficiency predisposes ductal cells to malignant transformation, manifesting in IPMN-associated and distant PDAC similar to human IPMN-PDAC.
IPMN-Associated PDAC in Pten
DDuct/DDuct
Mice Arises From Ductal Cells
To determine whether IPMN-PDAC in Pten Figure 3A) to ablate Pten in acinar cells. We injected mice with tamoxifen at 4 weeks of age (Supplementary Figure 3B) , assessed recombination at 4 months of age, and analyzed pancreata for the presence of premalignant lesions or PDAC at 12 to 13 months (n ¼ 9). Despite efficient recombination and expression of YFP in the acinar cell compartment (Supplementary Figure 3C) , pancreatic ducts appeared normal and premalignant lesions were not observed in Pten DAcinar/DAcinar mice (Supplementary Figure 3D and Table 1 ). These results suggest that human IPMN and the Pten DDuct/DDuct IPMN mouse model exhibit a similar subtype-specific pattern of Ras signaling activation.
We next examined whether Erk activation was associated with acquisition of spontaneous Kras mutations. For this, we first performed allele-specific PCR for the G12D Kras mutation, commonly found in human IPMN, 10 on DNA from section areas containing histologically normal tissue, IPMN, or IPMN/PDAC areas in Pten DDuct/DDuct mice. As expected, the wild-type G12 DNA sequence was amplified from all samples (Supplementary Figure 4B) . The G12D mutation was amplified in samples from pancreatobiliary IPMN lesions, but not normal tissue or oncocytic IPMN (Supplementary Figure 4B , lane 8; Table 1 ). Notably, we detected Kras G12D in only 3 of 15 pancreatobiliary IPMN, and all IPMN lesions with this mutation exhibited microor macro-invasion (Supplementary Figure 4B , lane 4 vs lane 6; Table 1 ). To further examine whether additional variant alleles for Kras G12 are present in Pten DDuct/DDuct mice, we performed a more sensitive multiplexed droplet digital PCR with probes to detect the G12D, G12C, G12R, and G12V variant alleles in a subset of samples where sufficient material was left ( Figure 4D and Supplementary Figure 4C and D) . These analyses confirmed our previous results and additionally indicated that 2 more pancreatobiliary IPMNs were positive for Kras mutant alleles, including one that was invasive. We also detected a Kras mutation in 1 oncocytic IPMN that had active Erk signaling in the cyst wall ( Figure 4D and Supplementary Figure 4A) , suggesting that the cyst wall developed the Kras mutation independently of the oncocytic papillary nodule, which was not pErk positive (Supplementary Figure 4A) . This raised the possibility that the Kras mutations could arise after IPMN initiation and be more important for IPMN progression. In support of this, we detected 2 different Kras mutations in the large IPMN-PDAC when the Kras variant probes were assayed individually ( Figure 4D, mouse #64) . Moreover, the invasive components of the pancreatobiliary IPMN were often more uniformly pErk-positive than the papillary nodules (Figure 4Ai , outlined area vs area denoted with asterisks; Figure 4Aii vs 4B), implying that Ras activation in the absence of Pten can be a late event associated with invasion in the context of pancreatobiliary IPMN. Importantly, no Kras G12 mutations were detected in the invasive oncocytic IPMN ( Figure 4D and Supplementary Figure 4D, mouse #98) . This suggests that, as in human disease, Kras mutations are predominantly associated with the development of pancreatobiliary, but not oncocytic IPMN.
To further confirm the link between Ras activation and IPMN progression but not initiation, we examined whether Erk signaling was activated in microscopic precursor lesions potentially preceding IPMN in Pten DDuct/DDuct mice. To investigate this, we analyzed Pten DDuct/DDuct mice devoid of macroscopic IPMN at 6 to 14 months (n ¼ 27). In this cohort, we observed microscopic lesions consisting of single-cell-layered intraductal papillae that were occasionally large enough to contain branched structures ( Figure 4E , 4 mice with 1 lesion each). Based on their similarity with pancreatobiliary IPMN, we designated these lesions prepancreatobiliary-IPMN. A second type of lesion consisted of papillae that had a diffuse eosinophilic cytoplasm and round nuclei randomly localized within the cell ( Figure 4F , 4 mice with at least 1 lesion). In some cases, these papillae had a dense multilayered epithelium, resembling macroscopic oncocytic IPMN. Therefore, we designated these lesions pre-oncocytic-IPMN. If Ras activation was important for the induction of these microscopic lesions, pErk should be detected. However, neither pre-pancreatobiliary-IPMN nor pre-oncocytic-IPMN ( Figure 4G and H) exhibited the uniformly strong positive pErk staining observed in invasive portions of pancreatobiliary IPMN (Figure 4Ai,Aii and B) . Combined, the absence of pErk in microscopic lesions and the progressive acquisition of pErk signal during the development of pancreatobiliary IPMN-PDAC suggests that
Ras activation in Pten
DDuct/DDuct mice is a later event during progression of pancreatobiliary IPMN to PDAC.
Oncogenic Kras Promotes IPMN and PDAC Formation in the Absence of Pten
To test whether Kras activation in the absence of Pten promotes pancreatobiliary IPMN and its invasion, we crossed LSL-Kras G12D mice (hereafter referred to as Kras ) mice ( Figure 5A ). Expression of Kras G12D and ablation of Pten was induced by injecting 4-weekold mice 3 times with tamoxifen ( Figure 5B ). To assess IPMN and PDAC formation, we followed Kras 
;Pten
DDuct/DDuct mice ( Figure 5C , green arrow), whereas additional dilation of the main pancreatic duct was observed in 10 of 14 mice ( Figure 5C , black arrow). Analysis of pancreatic sections revealed extensive papillae, resembling IPMN, lining the common duct (Supplementary Figure 5A , curved double-headed arrow) and the main and large pancreatic ducts ( Figure 5D and E, asterisks). The peribiliary glands of the common duct were expanded (Supplementary Figure 5A, arrow) . Consistent with detection of the Kras G12D mutation in IPMN-associated PDAC in Pten 
DDuct/DDuct mice exhibited a fully penetrant phenotype of invasive PDAC (Figure 5D-F) . The rapid and widespread formation of papillae and invasion along the common and main pancreatic duct suggests that activation of Kras and loss of Pten is sufficient to induce invasive IPMN in ductal cells lining the common and main pancreatic ducts.
Pten Reduction and Oncogenic Kras Synergistically Induce Preneoplastic Lesions From Ductal Cells
Expression of Kras G12D alone in ductal cells induces occasional PanIN lesions in a subset of mice by 8 to 16 months, 22 whereas heterozygous loss of Pten produced = Figure 5 . Synergy between Pten reduction and oncogenic Kras in the induction of IPMN-PDAC from ductal cells. ;Pten DDuct/þ mice were injected with TM on postnatal days 28, 30, and 32 and killed at their humane endpoint or at specific time points, respectively. In situ (C, G) and tiled hematoxylin/eosin images (D, H) of the pancreas in Kras G12D ;Pten DDuct/DDuct and Kras G12D ;Pten DDuct/þ mice at 9 weeks and 6 months, respectively. Black arrows denote lesions in the main pancreatic duct and green arrows in the common duct. Representative low-(E, I) and high-power (F, J) images of hematoxylin/eosin-stained pancreatic sections from Kras no discernable phenotype by 12 months of age (see controls in Figures 1 and 2 Figure 5A and B). (Figure 5E and F; Supplementary Figure 5A , curved double-headed arrow), expressed the YFP lineage marker and were Muc1-positive, but Muc2-negative (Supplementary Figure 5B-D) . However, some YFP þ
Muc1
þ Muc2 À papillae also contained gastrictype epithelium (Supplementary Figure 5I-L In Pten DDuct/DDuct mice, Kras mutations were associated with invasion of pancreatobiliary IPMN ( Figure 4D and Table 1 Figure 6F ) and unaffected areas ( Figure 6H ). pERK signal was present in a portion of the IPMN (Figure 6Bi , boxed area magnified in 6C), the invasive glands (Figure 6Bi, arrow) , and the IPMN-associated PDAC (Figure 6Bii , boxed area magnified in Figure 6D ). This case study suggests that PTEN reduction is associated with IPMN development, but strong activation of RAS signaling with progression to invasive PDAC. Thus, as in our mouse models, both KRAS activation and PTEN loss appear to be associated with invasive pancreatobiliary IPMN in humans.
Discussion
We show here that PTEN loss with or without activation of Ras signaling in pancreatic ductal cells of mice recapitulates many clinicopathological features of human main-duct IPMN. In contrast to previously described mouse models exhibiting IPMN, [11] [12] [13] [14] [15] Pten DDuct/DDuct and Kras G12D ;Pten DDuct/þ mice developed macroscopic, focal lesions within the ductal tree, spontaneously acquired secondary genetic mutations, and progressed to PDAC in the context of predominantly normal pancreatic parenchyma. These features are similar to the stochastic formation of precancerous lesions and tumors presumed to underlie PDAC development in humans.
Similar to human IPMN, our mouse models developed solid, isolated nodules on the walls of enlarged ducts (like mural nodules) in the absence of widespread tissue changes. The presence of a mural nodule is a clinically relevant criterion for assessing the malignant potential of a human pancreatic cyst. 3, 29 Because nodules in Pten DDuct/DDuct mice become invasive, this mouse model could help define additional events leading to the transformation of IPMN into PDAC. Furthermore, we observed IPMN lesions of multiple different subtypes, namely pancreatobiliary and oncocytic IPMN in Pten DDuct/DDuct mice and pancreatobiliary and gastric IPMN in Kras G12D ;Pten DDuct/þ mice. The IPMN subtypes in our mouse models showed characteristics highly similar to subtype-specific features observed in human IPMN. First, mutation biases observed in human IPMN were recapitulated in our mouse models. Specifically, consistent with Kras mutations being rare in human oncocytic IPMN, 9,10,26 Kras G12D mutations or highly active Erk signaling were not detected in oncocytic IPMN of Pten DDuct/DDuct mice. Furthermore, Kras mutations were associated with gastric and pancreatobiliary IPMN in our mouse models, which is consistent with the higher rate of KRAS mutations in these subtypes in humans. 9, 26 Second, Kras G12D ;Pten DDuct/þ mice displayed pancreatobiliary IPMN or pre-IPMN nodules that were continuous with gastric-type epithelium along the large pancreatic ducts. A highly similar phenomenon has been observed in multiple subtypes of human IPMN, which has led to the hypothesis that the gastric phenotype is the "null" phenotype and precedes the formation of other IPMN subtypes. 27 The Kras G12D ;Pten DDuct/þ model now presents an opportunity to dissect whether these lesions have a shared lineage or whether the gastric epithelium arises secondarily to the IPMN lesion. Given the impact of IPMN subtype identity on clinical prognosis, 2,3 dissecting the mechanisms that underlie initiation and progression of distinct IPMN subtypes could pave the way for the development of subtype-specific therapies of IPMN-PDAC.
Previous studies have shown that Pten inactivation in embryonic pancreatic precursor cells leads to expansion of centroacinar cells and ultimately progression to PDAC. 30 In contrast, we found that postnatal Pten deletion in ductal cells, including centroacinar cells, preferentially stimulated proliferation of cells in large ducts and had little effect on centroacinar cells. Similarly, combined Pten deletion and expression of oncogenic Kras in embryonic pancreatic precursor cells failed to induce IPMN, 28, 31 in stark contrast to our observation after Pten deletion and Kras activation in postnatal ductal cells. Moreover, we found that IPMN formed only in response to ductal cell-specific, but not acinar cell-specific, Pten deletion. These observations illustrate that the phenotype caused by PDAC-associated genetic mutations is highly context-dependent. Therefore, inducing genetic mutations associated with human PDAC in specific cell types will help generate informative animal models to delineate the mechanistic underpinnings of human PDAC.
We demonstrate a ductal origin of IPMN lesions and associated PDAC in our genetic models. The similarity of the Pten DDuct/DDuct model to human IPMN suggests that a spontaneous loss of PTEN in ductal cells during adult life could predispose to IPMN. This idea is consistent with human studies showing that mutations in the PTEN/PI3K pathway are more common in IPMN-associated PDAC than in conventional PDAC. [4] [5] [6] [7] [8] However, not all Kras
G12D
;Pten DDuct/þ mice showed Pten loss of heterozygosity. It is possible that posttranslational or epigenetic silencing mechanisms could also lead to PTEN loss, as shown in other contexts. 32 Further study of potential mechanisms underlying PTEN loss in IPMN-associated PDAC is clearly necessary. Here, cell lines derived from human or mouse IPMN-PDAC could help define molecular mechanisms.
We further observed synergy between reduced Pten dosage and Kras activation in IPMN formation from ductal cells and progression to PDAC. The most established function of PTEN is to restrain activity of the PI3K signaling pathway. PI3K is also activated by Ras signaling, arguing that high PTEN activity in ductal cells could suppress the transformative effects of oncogenic Kras. Consistent with this idea, ductal cell-specific expression of Kras G12D in the context of wild-type Pten had surprisingly little effect; the induction of a limited number of PanIN lesions in a subset of Kras
-expressing mice being the only abnormality. 22 Here we observed more efficient induction of PanIN, pre-IPMN, and IPMN when Kras G12D was expressed in the context of reduced PTEN, showing that PTEN indeed counteracts effects of oncogenic Kras in ductal cells. If the combined acquisition of PTEN loss and RAS activation we observed in a case of human pancreatobiliary IPMN-PDAC was verified in a larger number of cases, these features could become markers to distinguish IPMN with high and low malignant potential to inform patient selection for therapeutic intervention. In fact, reducing hyperinsulinemia-induced PI3K signaling through lifestyle modifications or pharmaceutical inhibition could reduce the risks of IPMN progression. Further studies examining how closely these mouse models recapitulate molecular aspects of human disease with regard to the accumulation of other IPMN-associated genetic and transcriptional changes could enable discovery of additional drivers of IPMN initiation and malignant progression.
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